Request Demo
Last update 08 May 2025
Hepatitis C virus NS 5 protein x RNA polymerase
Last update 08 May 2025
Basic Info
Related Targets |
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
EUCTR2007-000328-42-GB
A clinical pharmacology study to determine the pharmacokinetic , safety and tolerability profile and antiviral activity of multiple oral doses of A-831 in otherwise healthy male Hepatitis C carriers with compensated liver disease. - Clinical pharmacology study of A-831 in Hepatitis C carriers
NCT00522808
A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease
100 Clinical Results associated with Hepatitis C virus NS 5 protein x RNA polymerase
Login to view more data
100 Translational Medicine associated with Hepatitis C virus NS 5 protein x RNA polymerase
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free